Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective increased by Citigroup from $31.00 to $32.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on the stock. TD Cowen cut their price objective on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. Morgan Stanley increased their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the company an “overweight” rating in a research report on Friday, August 21st. Cantor Fitzgerald increased their target price on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday. William Blair cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 3rd. Finally, Barclays dropped their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $32.00 and set an “overweight” rating on the stock in a research report on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $34.42.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $14.51 on Friday. The stock has a market cap of $1.43 billion, a P/E ratio of -2.48 and a beta of 0.31. The stock has a 50 day moving average of $23.88 and a 200-day moving average of $24.43. Ultragenyx Pharmaceutical has a 52 week low of $12.73 and a 52 week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. The company had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business’s revenue was up 28.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.17) EPS. As a group, equities analysts predict that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RARE. Versant Capital Management Inc raised its holdings in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,001 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth about $48,000. Harbor Investment Advisory LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $52,000. Parallel Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares in the last quarter. Finally, Leonteq Securities AG boosted its stake in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,333 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA granted full approval to FAYUVI for pediatric patients with Sanfilippo syndrome Type A, also known as MPS IIIA. It is the first approved treatment for the fatal neurodegenerative disease, creating a new commercial opportunity for Ultragenyx where no prior therapy existed. Clinical data showed durable benefit, including a 23.5-point cognitive advantage versus natural history in the pivotal analysis. Ultragenyx Announces Approval of FAYUVI Gene Therapy
• Positive Sentiment: FAYUVI carries a reported $3.95 million list price, potentially making it a significant revenue contributor despite the disease’s small patient population. Ultragenyx expects shipments to qualified treatment centers within 30–60 days and will provide insurance and treatment-access support through its UltraCare program. Ultragenyx Sets $3.95m List Price for Fatal Rare Disease Therapy
• Positive Sentiment: The approval is Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company also received a Priority Review Voucher, which could accelerate development or potentially have financial value. US FDA Approves Ultragenyx’s Gene Therapy
• Positive Sentiment: Analysts raised targets after the approval: Cantor Fitzgerald and Canaccord Genuity moved to $39, Citi to $32, and Morgan Stanley to $20. Citi and Canaccord maintained bullish ratings, while Morgan Stanley remained equal weight. Ultragenyx Stock Jumps on Fayuvi Approval and Analyst Target
• Neutral Sentiment: The commercial opportunity is promising but limited by the ultra-rare population. Successful sales will depend on identifying eligible children, establishing treatment centers, securing insurer reimbursement, and managing the complexity of one-time gene-therapy administration.
• Negative Sentiment: FAYUVI’s label includes risks such as liver toxicity, low platelet counts, infusion reactions, thrombotic microangiopathy, and potential malignancy. Long-term safety and real-world adoption remain important uncertainties.
• Negative Sentiment: A Pomerantz law-firm investigation adds an overhang, while the earlier failed Angelman syndrome trial remains a reminder of Ultragenyx’s clinical-development risk. Pomerantz Investor Alert

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.